Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma

Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma

Izak Faiena,1,2 Amy L Cummings,3 Anna M Crosetti,3 Allan J Pantuck,1,2 Karim Chamie,1,2 Alexandra Drakaki1–3 1Department of Urology, 2Institute of Urologic Oncology, 3Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine at University of California,...

Full description

Bibliographic Details
Main Authors: Faiena I, Cummings AL, Crosetti AM, Pantuck AJ, Chamie K, Drakaki A
Format: Article
Language:English
Published: Dove Medical Press 2018-01-01
Series:Drug Design, Development and Therapy
Subjects:
Durvalumab
checkpoint inhibitors
metastatic urothelial carcinoma
Online Access:https://www.dovepress.com/durvalumab-an-investigational-anti-pd-l1-monoclonal-antibody-for-the-t-peer-reviewed-article-DDDT

Internet

https://www.dovepress.com/durvalumab-an-investigational-anti-pd-l1-monoclonal-antibody-for-the-t-peer-reviewed-article-DDDT

Similar Items